A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosis
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new antibody, Anti-pC, can identify fibroblasts actively synthesizing collagen. This tool helps assess fibrotic lung disease by visualizing collagen production in human tissue biopsies.
Area Of Science
- Biochemistry
- Immunology
- Pathology
Background
- Excessive collagen deposition is key in fibrosis development.
- Early fibrosis is more responsive to treatment than advanced scarring.
- Current methods lack a simple way to assess fibroblast collagen synthesis in human tissues.
Purpose Of The Study
- To develop and characterize a monoclonal antibody (Anti-pC) specific for the carboxyterminal propeptide of type I procollagen.
- To determine if Anti-pC staining correlates with active collagen synthesis in fibroblasts.
- To evaluate Anti-pC as a potential clinical tool for assessing fibrotic activity.
Main Methods
- Developed a monoclonal antibody (Anti-pC) targeting the carboxyterminal propeptide of type I procollagen.
- Stained embryonic and adult chicken tendon to correlate Anti-pC staining with collagen synthesis.
- Applied Anti-pC staining to lung biopsies from patients with fibrotic lung disease and normal controls.
Main Results
- Embryonic chick tendon fibroblasts actively synthesizing collagen showed strong Anti-pC staining.
- Quiescent adult tendon fibroblasts and normal human lung tissue did not stain with Anti-pC.
- Fibrotic lung disease biopsies revealed intense Anti-pC staining in interstitial and intraalveolar fibroblasts.
Conclusions
- Anti-pC antibody specifically visualizes fibroblasts actively synthesizing type I collagen.
- The staining pattern suggests fibrosis is linked to an altered fibroblast collagen-synthesizing phenotype.
- Anti-pC shows promise as a clinical tool for evaluating fibrogenic activity in tissue injury.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.